NanoRepro AG (NN6) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of NanoRepro AG stock €4.70, price €1.57, upside +200.0%, quality 68 out of 100. Rating: strongly undervalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range €1.22 – €8.45 · fair‑value band €3.95 – €5.52 · the €1.57 price screens below the €4.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow NanoRepro in your weekly email
Every Wednesday you see whether NanoRepro is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally.
Show moreShow less
The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preventive healthcare line products.
The company also develops and commercializes immunochromatographic lateral flow tests; and tests for hospitals and medical practices. The company is headquartered in Marburg, Germany.
Stock analysis
NanoRepro AG (NN6) currently trades at €1.57, while our model-based Fair Value estimate is €4.70, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of €14.68 per share, and 5 of the 6 models we run sit above the €1.57 price.
Bear case: the Asset-Based group reads lowest at €0.6500, and 1 of the 6 models stay below the price. Data coverage for this calculation is low.
Scenario range: €3.95 (bear) to €5.52 (bull), the price of €1.57 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
NanoRepro AG reported revenue of €4.7M in FY2025 versus €163M in FY2021, a compound −58.9%/yr. Reported net income was −€2.0M in FY2025.
Key figures
Market cap €19.7M Micro · P/S ratio 4.65 · EPS (TTM) €−0.1400 · Net margin −45.8% · Return on equity −5.4% · Return on assets (EBIT) 4.2% (5-year average) · Operating margin −60.0% · Revenue (TTM) €4.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 200%, NN6 screens cheaper than that median.
Fair Value models
Bear€3.95Fair Value €4.70Bull€5.52
Price €1.57 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−50.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.8%
Start year 2020 (pandemic). Over 10 years: +22.6% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−97.0% (2019) → −78.0% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on assets−5.4% · Below median
Net margin (12 months)−45.8% · Bottom 25%
Operating margin (12 months)−60.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−29.3% · Bottom 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NanoRepro AG Fair Value". https://www.fairvalue-calculator.com/stock/NN6
Frequently asked questions
Is NanoRepro AG (NN6) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of €4.70 versus a price of €1.57, about +200% upside (undervalued).
What is the fair value of NN6?
Our model-based fair value for NanoRepro AG is €4.70 (as of Nov 8, 2026), built from audited fundamentals. The current price: €1.57.
What is the quality score of NN6?
NanoRepro AG has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NanoRepro AG (NN6)?
Our model-based price target is the fair value of €4.70 (as of Nov 8, 2026) from 6 valuation models. Cautious scenario €3.95, optimistic scenario €5.52. It is a calculation from audited fundamentals, not an analyst target.
What is the NanoRepro AG stock forecast for 2026?
Our models put fair value at €4.70, about +200% upside versus a price of €1.57 (undervalued). Cautious scenario €3.95, optimistic scenario €5.52. The calculation is refreshed regularly with new filings.
What is the revenue of NanoRepro AG (NN6)?
NanoRepro AG reported trailing-twelve-month revenue of about €4.3M (latest available figure, as of Nov 8, 2026).
What growth is priced into NanoRepro AG (NN6)?
For today's price to be fair in a discounted-cash-flow model, NanoRepro AG would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -22.8 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of NN6 use?
Our models discount NanoRepro AG at 8.3 %: a base by market capitalisation (nano), damped by beta 0.44, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NanoRepro AG that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has NanoRepro AG (NN6) delivered so far?
Over the past 5 years revenue at NanoRepro AG grew -22.8 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NanoRepro AG (NN6) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into NanoRepro AG (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NanoRepro AG (NN6)?
The free-cash-flow yield on the price is 47.91 %: that much free cash flow NanoRepro AG produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NanoRepro AG (NN6)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NanoRepro AG it is €4.70 per share (as of Nov 8, 2026), against a price of €1.57. It is the blended result of 6 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is NanoRepro AG stock overvalued or undervalued in 2026?
As of Nov 8, 2026, NN6 trades below its calculated fair value: price €1.57, fair value €4.70, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NN6?
No. The price is what the market pays today (€1.57); the fair value is what the company's own numbers justify (€4.70). For NanoRepro AG the two are €3.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is NanoRepro AG worth?
The market values NanoRepro AG at about €19.7M (market capitalisation, as of Nov 8, 2026). Per share that is €1.57; our models calculate a fair value of €4.70 per share.
What do the bullish and bearish scenarios say about NN6?
Our models span a range for NanoRepro AG: cautious scenario €3.95, base €4.70, optimistic €5.52 per share (as of Nov 8, 2026, price €1.57). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NanoRepro AG (NN6)?
Balance-sheet figures for NanoRepro AG (as of Nov 8, 2026): return on equity −5.4%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is NN6 from its 52-week high?
NanoRepro AG trades at €1.57, about 32% below its 52-week high of €2.29 and 13% above the low of €1.38 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €4.70 is for.
Which stocks are comparable to NanoRepro AG?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NanoRepro AG stock attractive at the current price?
The data as of Nov 8, 2026: price €1.57, calculated fair value €4.70 (+200%), Quality Score 68/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NN6 calculated?
We run NanoRepro AG through 6 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of €4.70 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NanoRepro AG currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NanoRepro AG (NN6)?
The closing price on Nov 6, 2026 was €1.57. Our model-based fair value is €4.70, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NanoRepro AG right now?
The price is below even our cautious bear case (€3.95). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of NanoRepro AG
How large is the market capitalisation of NanoRepro AG (NN6)?
The market capitalisation of NanoRepro AG is €19.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NanoRepro AG (NN6)?
The price-to-sales ratio of NanoRepro AG is 4.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NanoRepro AG (NN6)?
Earnings per share at NanoRepro AG are €−0.1400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of NanoRepro AG (NN6)?
The net margin of NanoRepro AG is −45.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NanoRepro AG (NN6)?
The return on equity (ROE) of NanoRepro AG is −5.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NanoRepro AG (NN6)?
On an EBIT basis the return on assets of NanoRepro AG is 4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NanoRepro AG (NN6)?
The operating margin of NanoRepro AG is −60.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NanoRepro AG (NN6)?
Revenue at NanoRepro AG is growing −29.3% versus a year earlier (3y avg −50.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does NanoRepro AG (NN6) hold?
NanoRepro AG holds more cash than debt, €7.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch NanoRepro AG in the live analysis
One click puts NanoRepro AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026